HUNTINGTON DISEASE
Clinical trials for HUNTINGTON DISEASE explained in plain language.
Never miss a new study
Get alerted when new HUNTINGTON DISEASE trials appear
Sign up with your email to follow new studies for HUNTINGTON DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Huntington's drug enters human testing
Disease control OngoingThis early-stage study is testing a new injection called ER2001 in people with early Huntington's disease. The main goals are to check if the treatment is safe, how the body processes it, and to look for early signs it might help. Participants receive weekly injections for 6 week…
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE1, PHASE2 • Sponsor: ExoRNA Bioscience • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
New Huntington's drug enters next safety check
Disease control OngoingThis is a very early study to check the safety of a new drug called ER2001 for people with early Huntington's disease. It will give 9 participants who were in a previous study weekly injections for 6 weeks to see how their bodies handle the drug and if there are any side effects.…
Matched conditions: HUNTINGTON DISEASE
Phase: EARLY_PHASE1 • Sponsor: ExoRNA Bioscience • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Can a pill help Huntington's patients speak and walk better?
Disease control OngoingThis study is testing if a medication called deutetrabenazine can help improve speech clarity and walking stability in people with Huntington's disease. Over two years, 30 participants will have their speech and movement carefully measured before and after starting the drug. The …
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE2, PHASE3 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug trial aims to slow devastating brain disease
Disease control OngoingThis study is testing an experimental drug called tominersen to see if it is safe and can slow the progression of Huntington's disease in people who are in the very early stages. About 300 participants will receive either the drug or a placebo (inactive substance) for 16 months, …
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Brain injection trial offers hope for halting Huntington's
Disease control OngoingThis early-stage study is testing a one-time gene therapy called AB-1001, delivered directly into the brain, in a small group of adults with early Huntington's disease. The main goals are to see if the treatment is safe and to look for early signs that it might slow the disease. …
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Huntington's drug trial extends for over four years to test Long-Term safety
Disease control OngoingThis study is a long-term extension for people who completed an earlier trial of votoplam for Huntington's disease. It aims to monitor the safety and effects of the drug over an additional 54 months. All participants will receive the active drug, and researchers will track side e…
Matched conditions: HUNTINGTON DISEASE
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 02, 2026 15:23 UTC